Rok Narobe
@rnarobe.bsky.social
Reposted by Rok Narobe
May I recommend this series:
Published annually by Pfizer Merck Takeda and others
Review of synthetic methods to marketed drugs
Great look at the current state of pharma synthesis
Published annually by Pfizer Merck Takeda and others
Review of synthetic methods to marketed drugs
Great look at the current state of pharma synthesis
Synthetic Approaches to the New Drugs Approved during 2023
This review is the next installment of an annual series that discusses the synthetic routes to access 28 small molecule drugs that were approved worldwide in 2023. A brief description of each drug’s m...
pubs.acs.org
November 13, 2025 at 12:58 AM
May I recommend this series:
Published annually by Pfizer Merck Takeda and others
Review of synthetic methods to marketed drugs
Great look at the current state of pharma synthesis
Published annually by Pfizer Merck Takeda and others
Review of synthetic methods to marketed drugs
Great look at the current state of pharma synthesis
Reposted by Rok Narobe
Commercial/lrg scale of API generally avoids glove-box type reactions - this annual review is chock full of “regular” reactions used for scale up
Synthetic Approaches to the New Drugs Approved during 2023
This review is the next installment of an annual series that discusses the synthetic routes to access 28 small molecule drugs that were approved worldwide in 2023. A brief description of each drug’s m...
pubs.acs.org
June 4, 2025 at 9:12 PM
Commercial/lrg scale of API generally avoids glove-box type reactions - this annual review is chock full of “regular” reactions used for scale up